Announcements

Sanjay Chandru Keswani, Chief Medical Officer of Neurocrine Biosciences Inc. (NASDAQ:NBIX), filed a Form 4 on September 15, 2026, disclosing changes in beneficial ownership of common stock stemming from the vesting of performance restricted stock units on September 11, 2026.

Darin Lippoldt, Chief Legal Officer of Neurocrine Biosciences Inc., filed a Form 4 on September 15, 2026, disclosing the vesting of performance restricted stock units and a related tax withholding transaction dated September 11, 2026.

A Form 4 filed on September 15, 2026 reports that Chris Diorio, Ph.D., Chief Executive Officer and Director of Impinj Inc, disposed of 10,000 shares of common stock on September 14, 2026 under a Rule 10b5-1 trading plan.

Jack Higgins, Chief Scientific Officer of Immunome Inc. (NASDAQ:IMNM), filed a Form 4 on September 15, 2026, reporting multiple transactions in common stock and employee stock options dated September 11, 2026.

Stanley J. Sutula III, Chief Financial Officer of Colgate-Palmolive Co, filed a Form 4 on September 15, 2026, disclosing three share withholding transactions on common stock tied to the vesting of restricted stock units between September 11 and September 13, 2026.

David Fortunato, CEO and President of Wealthfront Corp (NASDAQ:WLTH), filed a Form 4 on September 15, 2026, disclosing option exercises and a share disposition by his spouse on September 11, 2026.

Raman Singh, a director of Liquidia Corp, filed a Form 4 on September 15, 2026, disclosing the exercise of non-qualified stock options and subsequent sales of common stock on September 11 and September 14, 2026.